With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.122833-04-9,2-Methoxy-4-(4-methylpiperazin-1-yl)aniline,as a common compound, the synthetic route is as follows.
To a stirred solution of 2,5-dichloro-4-(3-fluoro-5-nitrophenoxy)-7-((2-(trimethylsilyl)ethoxy) methyl)-7H-pyrrolo[2,3-d]pyrimidine (2, 0.25 g, 0.5 mmol) in t-BuOH ( 10 mL), 2-methoxy-4-(4- methylpiperazin- l -yl)aniline (3, 0.1 16 g, 0.5 mmol), Pd2(dba)3 ( 13 mg, 0.01 mmol), X-PHOS (12 mg, 0.02 mmol), 2C03 (0.145 g, 1.0 mmol) were added and stirred at 90 C for 14 h. Reaction was monitored by TLC and LCMS. After completion of the reaction, reaction mixture was concentrated under reduced pressure, water was added, extracted with ethyl acetate. Organic layer was washed with brine, dried over anhydrous sodium sulfate and evaporated to dryness. Crude product was purified by column chromatography using 4% MeOH-DCM to afford 5-chloro-4-(3-fluoro-5-nitrophenoxy)-N-(2- methoxy-4-(4-methylpiperazin- l -yl)phenyl)-7-((2-(trimethylsilyl)ethoxy) methyl)-7H-pyrrolo[2,3- d]pyrimidin-2-amine (4, 0.233 g, 67%). NMR (400 MHz, CDC13): delta 8.10 (s, 1 H), 7.90-7.80 (d, 1 H), 7.42-7.40 (d, 1H), 7.30 (s, 1 H), 6.90 (s, 1H), 6.50 (s, 1 H), 6.40-6.30 (d, 1 H), 5.50 (s, 2H), 3.80 (s, 3H), 3.60-3.50 (t, 2H), 3.20-3.10 (m, 4H), 2.70-2.60 (m, 4H), 2.40 (s, 3H), 1.00-0.95 (t, 2H), 0.2 (s, 9H)., 122833-04-9
The synthetic route of 122833-04-9 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; GATEKEEPER PHARMACEUTICAL, INC.; GRAY, Nathanael, S.; ZHOU, Wenjun; WO2011/79231; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics